


# Supplementary Figure S5



**Supplementary Figure S5: CAR-T degranulation against multiple B-cell malignancies cell lines and patient samples**

**(a)** Degranulation of various CAR-T cells when co-cultured with three B-ALL cell lines (SEM, RS411, and Nalm6), **(b)** Degranulation of various CAR-T cells when co-cultured with three lymphoma cell lines (TOLEDO-DLBCL, Namalwa-Burkitt's Lymphoma, and JEKO-Mantle Cell Lymphoma). **(c)** Three primary B-ALL tumor samples evaluated for CD19 and CD72 surface expression, and their ability to trigger CAR-T degranulation. FACS histograms display either CD19 or CD72 surface expression measured by flow cytometry. *In vitro* FACS-based degranulation assay where target cells were cocultured with either CD19, CD72, or Empty CAR-T's at a 2:1 E:T ratio along with CD107a antibody and Golgistop for 6-hours prior to analysis by FACS.